Connect with us
Alfasigma has acquired the marketing rights for Jyseleca, a JAK1 inhibitor drug used for rheumatoid arthritis and ulcerative colitis, following European Medicines Agency approval. This acquisition...
Oryzon Genomics shares rose 2.8% after receiving positive FDA feedback on vafidemstat for borderline personality disorder. The company plans a Phase III study with 350 patients...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
Sequentia Biotech plans to use new funds to expand its Mick-branded application for automated microbiome data analysis, targeting biopharmaceutical and biomedical sectors. The biotech, founded in...
Asabys Partners closed its second fund, Sahii II, at €180 million, surpassing the initial €150 million target. Supported by Banco Sabadell and other international investors, Sahii...
Multiply Labs has secured its first major collaboration with Legend Biotech to use robotic technology in cell therapy manufacturing. The partnership aims to improve efficiency and...
Brain Biotech shares surged 85%, fueled by news of a major deal with Royalty Pharma. However, the contract's full value, €128.88 million, is conditional on meeting...
Sysmex is advancing a five-year growth plan in Spain, expecting a 10% revenue increase in 2024. Key milestones include new hematology systems and partnerships, organic market...
Alfasigma, an Italian pharmaceutical company, absorbed Galapagos' Spanish subsidiary in September after board restructuring in June. The merger required regulatory clearance, which was not fully met,...
Luminova Pharma Group plans to invest heavily in modernizing and expanding Serra Pàmies laboratories in Reus to boost production of cardiovascular, diabetes, and psychotropic treatments. The...